A Phase Ib/II, Open-label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with CHOP or CHP-Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma

Protocol No
HOFFMANN-LAROCHE-GO40515
Principal Investigator
Mehdi Hamadani
Phase
I/II
Summary
Mosunetuzumab and polatuzumab vedotin are experimental drugs, which means health authorities have not approved mosunetuzumab or polatuzumab vedotin in combination with CHOP or CHP (or with any other combination) for the treatment of B-cell NHL or for any other disease. Both experimental drugs are designed to treat B-cell NHL. Mosunetuzumab may kill lymphoma cells by recruiting and activating immune cells. Polatuzumab vedotin is designed to deliver a potent chemotherapeutic drug to kill lymphoma cells. This study will test the safety and efficacy of combining these experimental drugs with chemotherapies used to treat B-cell NHL.
Description
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: